premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 09/22, Down 15.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MDT has triggered its stop at $79. To remain disciplined, we recommend covering the position at this time.
biotechnology / pharmaceutical
BUY
Aging demographics help. It's selling below 2x below its 5-year average, and has a 6% operating cash flow yield. He expects solid earnings next week.
biotechnology / pharmaceutical
premium

It’s a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly This $124 billion market cap manufacturer of medical devices ranging from insulin pumps to pacemakers is the world's largest in its class. It has raised dividends for 46 consecutive years. It has been buying back stock while maintaining steady cash reserves and trades at just 2.4x earnings. The resumption in surgical procedures as the pandemic calms down is expected to lead to substantial uplift in EPS going forward. We recommend setting a stop loss at $79, looking to achieve $117 -- upside over 25%. Yield 2.92% (Analysts’ price target is $117.13)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 15/21, Down 7%) Company has increased dividend for almost 50 years, however needs a good acquisition to grow. Stock price is low which creates a buying opportunity. Will continue to buy and hold.
biotechnology / pharmaceutical
HOLD
Relatively low growth at 3-5%, value stock with a 13.5-14.5x multiple. Couple of missteps. Competitive threats. One of the largest medical device companies. Tends to attract money flows when markets get volatile. Reports later in February. Mild inflationary pressures. OK dividend. OK to hold over time, but if you want more growth, pair it with something like BSX.
biotechnology / pharmaceutical
SELL
They've been executing badly. Sell this and buy EW-N
biotechnology / pharmaceutical
WAIT
MDT vs. BSX Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.
biotechnology / pharmaceutical
BUY
Healthcare is an interesting area, especially with a slant toward medical devices. This is a safe and steady name, significant track record of dividend increases.
biotechnology / pharmaceutical
BUY
They report Thursday. Boring, but he predicts stellar numbers. Their medical devices are being installed in record numbers post-pandemic. There's a lot of pent-up demand from all these delayed surgeries.
biotechnology / pharmaceutical
BUY on WEAKNESS
Allan Tong’s Discover Picks Up 14.68% since August 18, 2020 MDT was trading at $101. It has since climbed as high as $122.15, but now lockdowns are delaying elective surgeries, and the stock is starting to wobble around $117. Keep an eye on this, because continuing lockdowns and a general market pullback would make this a buy again. Right now, MDT is pricey, trading at a 43x PE, which is nearly double from last April and the highest level in 12 months. Its divvy pays nearly 2%. Analysts target the stock at $129.26, based on 17 buys and three holds. Read 2 Successful Past Picks: Nuvei & Medtronic for our full analysis.
biotechnology / pharmaceutical
TOP PICK
The global leader in med-tech space by revenue. It has increased dividends for 42 consecutive years. 9.4% total return for the last 5 years. Benefits from the aging demographics. Does a lot of tuck in acquisitions. The top line is growing at 9% in the last 10 years. (Analysts’ price target is $128.84)
biotechnology / pharmaceutical
BUY

Likes this medical device-maker. They presented at today's JPMorgan's healthcare conference. The stocked slipped 1% today after the company trimmed organic growth forecast this quarter because the explosion of Covid cases is forcing the postponement of medical procedures. This happened at a previous conference, so he's not surprised. The Covid issue is temporary and meanwhile more people will get vaccinated that will unleash pent-up demand for MDT's devices.

biotechnology / pharmaceutical
BUY

There is a backlog of elective surgeries. This is a good area of the industry to be in. She chose JNJ-N but MDT-N is a good candidate too.

biotechnology / pharmaceutical
BUY

A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.

biotechnology / pharmaceutical
BUY on WEAKNESS
Sales could be light, because people may be light, because it makes medical devices and people are postponing operations due to Covid. If MDT gets hit, buy it, because a Covid vaccine is coming. It reports Tuesday.
biotechnology / pharmaceutical
Showing 1 to 15 of 98 entries

Medtronic Inc(MDT-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 5

Stockchase rating for Medtronic Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Medtronic Inc(MDT-N) Frequently Asked Questions

What is Medtronic Inc stock symbol?

Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N

Is Medtronic Inc a buy or a sell?

In the last year, 5 stock analysts published opinions about MDT-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Medtronic Inc.

Is Medtronic Inc a good investment or a top pick?

Medtronic Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Medtronic Inc.

Why is Medtronic Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Medtronic Inc worth watching?

5 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.

What is Medtronic Inc stock price?

On 2022-12-02, Medtronic Inc (MDT-N) stock closed at a price of $79.62.